Pharmacotherapy for late-life depression.
Pharmacotherapy for late-life depression.
复制标题
DOI：
10.4088/jcp.7085tx2cj
复制
发表时间：
2011-01
期刊：
影响因子：
--
通讯作者：
Alexopoulos GS
中科院分区：
文献类型：
--
作者：
Alexopoulos GS
2001 年治疗老年患者重度抑郁症 (MDD) 的专家共识指南建议抗抑郁治疗与心理治疗相结合。最近的证据继续支持使用选择性5-羟色胺再摄取抑制剂和5-羟色胺-去甲肾上腺素再摄取抑制剂作为老年人的一线药物，尽管透皮单胺氧化酶抑制剂司来吉林在成年患者中显示出希望，但尚未在老年抑郁症中进行研究。非典型抗精神病药或其他药物的强化治疗可能对老年人的烦躁、精神病或耐药性 MDD 有益。自指南发布以来，在老年人群中进行的少数治疗研究的结果好坏参半，安慰剂反应率很高。需要更大规模的对照试验。
The 2001 expert consensus guidelines for treating major depressive disorder (MDD) in geriatric patients recommended antidepressant treatment in combination with psychotherapy. Recent evidence continues to support the use of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors as first-line agents in the elderly, and although the transdermal monoamine oxidase inhibitor selegilene has shown promise in adult patients, it has not been studied in geriatric depression. Augmentation therapy with atypical antipsychotics or other agents may provide benefits for agitated, psychotic, or resistant MDD in the elderly. The few treatment studies that have been conducted in the geriatric population since the publication of the guidelines have had mixed results and high placebo response rates. More large controlled trials are needed.